Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin

Christiane Gasse; Jennifer Hollowell; Christoph R. Meier; Walter E. Haefeli

doi:10.1160/TH05-03-0166

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2005; 94(03): 537-543
DOI: 10.1160/TH05-03-0166

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin

Christiane Gasse

¹Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Germany

,

Jennifer Hollowell

²AstraZeneca R&D, Mölndal, Sweden

,

Christoph R. Meier

³Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology &Toxicology, University of Basel, Switzerland

,

Walter E. Haefeli

¹Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Germany

› Institutsangaben

Abstract

Summary

Although drug interactions with warfarin are an important cause of excessive anticoagulation, their impact on the risk of serious bleeding is unknown. We therefore performed a cohort study and a nested case-control analysis to determine the risk of serious bleeding in 4152 patients (aged 40–84 years) with nonvalvular atrial fibrillation (AF) taking long-term warfarin (>3 months). The study population was drawn from the UK General Practice Research Database. More than half (58%) of eligible patients used potentially interacting drugs during continuous warfarin treatment. Among 45 identified cases of incident idiopathic bleeds (resulting in hospitalisation within 30 days or death within 7 days) and 143 matched controls, more cases than controls took ≥1 potentially interacting drug within the preceding 30 days (62.2% vs. 35.7%) and used >4 drugs (polypharmacy) within the preceding 90 days (80.0% vs. 66.4%). Conditional logistic regression analysis yielded an odds ratio (OR) of 3.4 (95% confidence interval [CI]: 1.4–8.5) for the risk of serious bleeding in patients treated with warfarin and ≥1 drugs potentially increasing the effect of warfarin vs. warfarin alone adjusted for polypharmacy, diabetes, hypertension, heart failure, and thyroid disease; the adjusted OR for the combined use of warfarin and aspirin vs. warfarin alone was 4.5 (95% CI: 1.1–18.1). We conclude that concurrent use of potentially interacting drugs with warfarin is associated with a 3 to 4.5-fold increased risk of serious bleeding in long-term warfarin users.

Keywords

Atrial fibrillation - bleeding - drug interactions - warfarin

Volltext

Referenzen

References
1 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.. Arch Intern Med 1994; 154: 1449-57.
2 Wells PS, Holbrook AM, Crowther NR. et al. Interactions of warfarin with drugs and food.. Ann Intern Med 1994; 121: 676-83.
3 Panneerselvam S, Baglin C, Lefort W. et al. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin.. Br J Haematol 1998; 103: 422-4.
4 Brigden ML, Kay C, Le A. et al. Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population.. Am J Hematol 1998; 59: 22-7.
5 Hylek EM, Heiman H, Skates SJ. et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation.. JAMA 1998; 279: 657-62.
6 Stockley IH. Stockley’s Drug Interactions. Sixth edition London: Pharmaceutical Press; 2002
7 Johnsen SP, Sorensen HT, Mellemkjoer L. et al. Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants.. Thromb Haemost 2001; 86: 563-8.
8 Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.. Am J Med 1993; 95: 315-28.
9 Clarke MF, Boardman HS. Interaction between warfarin and oral terbinafine. Systematic review of interaction profile of warfarin is needed.. BMJ 1998; 317: 205-6.
10 Shireman TI, Howard PA, Kresowik TF. et al. Combined anticoagulant–antiplatelet use and major bleeding events in elderly atrial fibrillation patients.. Stroke 2004; 35: 2362-7.
11 Jick SS, Kaye JA, Vasilakis-Scaramozza C. et al. Validity of the general practice research database.. Pharmacotherapy 2003; 23: 686-9.
12 Steffensen FH, Kristensen K, Ejlersen E. et al. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort.. J Intern Med 1997; 242: 497-503.
13 British National Formulary. Edition 41. London: Pharmaceutical Press; 2001
14 Guidelines on oral anticoagulation. third edition. Br J Haematol 1998; 101: 374-87.
15 Demirkan K, Stephens MA, Newman KP. et al. Response to warfarin and other oral anticoagulants: effects of disease state.. South Med J 2000; 93: 448-54.
16 Hirsh J, Dalen JE, Anderson DR. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: S8-S21.
17 Ansell J, Hirsh J, Poller L. et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.. Chest 2004; 126 (Suppl. 03) S204-S33.
18 Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. An update.. Clin Pharmacokinet 1996; 30: 416-44.
19 Visser LE, Penning-van Beest FJA, Kasbergen AAH. et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.. Thromb Haemost 2002; 88: 705-10.
20 Kucher N, Castellanos LR, Quiroz R. et al. Time trends in warfarin-associated hemorrhage.. Am J Cardiol 2004; 94: 403-6.
21 Hollowell J, Ruigomez A, Johansson S. et al. The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom.. Br J Gen Pract 2003; 53: 312-4.
22 Bates DW, Cullen DJ, Laird N. et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group.. JAMA 1995; 274: 29-34.
23 Buresly K, Eisenberg MJ, Zhang X. et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.. Arch Intern Med 2005; 165: 784-9.
24 Hansten P, Wittkowsky AK. Warfarin drug interactions. Ansell JE, Oertel LB, Wittkowsky AK. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines.. Wolters Kluwer Health, Inc.; St Louis (MO): 2004
25 Klasco RK. DRUGDEX® System. 1st ed. Thomson MICROMEDEX®. Greenwood Village (CO): 2004
26 Visser LE, Penning-van Beest FJA, Kasbergen AAH. et al. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants.. Clin Pharmacol Ther 2002; 71: 496-502.
27 Howard PA, Ellerbeck EF, Engelman KK. et al. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation.. Pharmacoepidemiol Drug Saf 2002; 11: 569-76.
28 Reynolds MW, Fahrbach K, Hauch O. et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis.. Chest 2004; 126: 1938-45.
29 Koo S, Kucher N, Nguyen PL. et al. The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage.. Arch Intern Med 2004; 164: 1557-60.
30 Kucher N, Conolly S, Beckman JA. et al. International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle.. Arch Intern Med 2004; 164: 2176-9.